LMD remains a devastating complication of cancer despite the significant improvement in overall survival of patients with metastatic melanoma with new effective systemic treatments, including selective BRAF inhibitors and anti-CTLA-4 antibody. This evidence concerns the gene CTLA4 and Langer mesomelic dysplasia.